Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
Company overview
Financial review
Conclusions
Appendix
References
Completed the transformation; laying the foundation for our future growth
Strategy
AH
Vx
OTC
FY 2014
Pre-portfolio
transformation
Alcon
Innovative
Sandoz Medicines
FY 2023
Focused
company
Pure-play
Innovative
Medicines
Operations
Core margin
FCF (USD)
as % of sales
Innovation
25.2%
11.1bn
19.1%
36.0%
13.2bn
29.0%
10 positive Ph3 readouts on assets
with significant sales potential
2014 figures reflecting revised free cash flow definition, 2023 figures reflect Continuing Operations. As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising
the Innovative Medicines Division and the continuing Corporate activities.
□ NOVARTIS | Reimagining Medicine.
Novartis Q4 Results | January 31, 2024
5
LOView entire presentation